Gemcitabine free base
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 123210

CAS#: 95058-81-4 (free base)

Description: Gemcitabine is an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis.


Price and Availability

Size
Price

1g
USD 80
20g
USD 450
200g
USD 3150
Size
Price

5g
USD 150
50g
USD 950
500g
USD 4950
Size
Price

10g
USD 250
100g
USD 1750
1kg
USD 6950

Gemcitabine free base, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 200 g may be 2 weeks.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 123210
Name: Gemcitabine free base
CAS#: 95058-81-4 (free base)
Chemical Formula: C9H11F2N3O4
Exact Mass: 263.07176
Molecular Weight: 263.2
Elemental Analysis: C, 41.07; H, 4.21; F, 14.44; N, 15.97; O, 24.31


Related CAS #: 95058-81-4 (free base)   122111-03-9 (HCl)    

Synonym: LY-188011; LY 188011; LY188011; Abbreviations: dFdC; dFdCyd; gemcitabine;Gemzar.

IUPAC/Chemical Name: 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

InChi Key: SDUQYLNIPVEERB-QPPQHZFASA-N

InChi Code: InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1

SMILES Code: O=C1N=C(N)C=CN1[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.90.01


References

1: Park JO, Oh DY, Hsu C, Chen JS, Chen LT, Orlando M, Kim JS, Lim HY. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat. 2015 Jul;47(3):343-61. doi: 10.4143/crt.2014.308. Epub 2015 May 18. Review. PubMed PMID: 25989801.

2: Maeda T, Tsuchiya M, Ishii J, Koda T, Kubota Y, Katagiri T, Tamura A, Otsuka Y, Shibuya K, Kaneko H. [A case of pancreatic cancer with distant metastasis successfully resected after neoadjuvant chemotherapy with a combination of S-1 and gemcitabine]. Gan To Kagaku Ryoho. 2014 Nov;41(12):2184-6. Review. Japanese. PubMed PMID: 25731464.

3: Ding X, Chen W, Fan H, Zhu B. Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy. Gene. 2015 Mar 15;559(1):31-7. doi: 10.1016/j.gene.2015.01.010. Epub 2015 Jan 10. Review. PubMed PMID: 25582275.

4: Wei MY, Zhuang YF, Wang WM. Gemcitabine for the treatment of patients with osteosarcoma. Asian Pac J Cancer Prev. 2014;15(17):7159-62. Review. PubMed PMID: 25227807.

5: de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014 Oct 15;741:8-16. doi: 10.1016/j.ejphar.2014.07.041. Epub 2014 Jul 30. Review. PubMed PMID: 25084222.

6: Nordh S, Ansari D, Andersson R. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review. World J Gastroenterol. 2014 Jul 14;20(26):8482-90. doi: 10.3748/wjg.v20.i26.8482. Review. PubMed PMID: 25024604; PubMed Central PMCID: PMC4093699.

7: Li Q, Yuan Z, Yan H, Wen Z, Zhang R, Cao B. Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer. Clin Ther. 2014 Jul 1;36(7):1054-63. doi: 10.1016/j.clinthera.2014.05.066. Epub 2014 Jun 27. Review. PubMed PMID: 24986485.

8: Khan MF, Gottesman S, Boyella R, Juneman E. Gemcitabine-induced cardiomyopathy: a case report and review of the literature. J Med Case Rep. 2014 Jun 23;8:220. doi: 10.1186/1752-1947-8-220. Review. PubMed PMID: 24957905; PubMed Central PMCID: PMC4086693.

9: Koga H, Miyoshi A, Nakamura J, Ide T, Kitahara K, Noshiro H. [A case of effective treatment with S-1/gemcitabine chemotherapy and resection for advanced pancreatic cancer with peritoneal dissemination]. Gan To Kagaku Ryoho. 2014 May;41(5):665-8. Review. Japanese. PubMed PMID: 24917019.

10: Borazanci E, Von Hoff DD. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2014 Sep;8(7):739-47. doi: 10.1586/17474124.2014.925799. Epub 2014 May 31. Review. PubMed PMID: 24882381.